-+ 0.00%
-+ 0.00%
-+ 0.00%

German Watchdog Finds Errors in Pentixapharm's FY24 Financial Statements

MT Newswires·10/05/2026 01:12:04
Listen to the news
01:12 AM EDT, 10/05/2026 (MT Newswires) -- Pentixapharm's (PTP.F) intangible assets and capital reserve for 2024 were overstated by 34.7 million euros and 21.6 million euros, respectively, the German Federal Financial Supervisory Authority, or Bafin, concluded following a financial investigation. The radiopharmaceutical development company said Oct. 2 that the error findings do not materially affect its operating business, liquidity, or business prospects. Pentixapharm maintained its 2026 guidance and resolved not to pursue a legal course against Bafin's decision.